| abstract |
Referred to a compound of formula (I); wherein R1, R2, R3 and R4 are, independently, H, halo, -ORA, -SRA, among others; A1, A2, A3, and A4 are independently H, halo, or alkyl; G1 is halo, -ORB, -SRB, among others; G2 is halo, -ORC, -SRC, among others; X and Z are, independently, O, S, or -NRD; and RA, RB, RC and RD are, independently, H or alkyl; where, when present, -ORB and -ORC are not both -OH. A selected compound is (S) - or (R) -3- (4-hydroxyphenyl) -3- (4-methoxyphenyl) -7- (trifluoromethyl) indolin-2-one. These compounds inhibit the proliferation of cancer cells and destroy ER alpha positive breast, ovarian and endometrial cancer cells, preventing reactivation of tumors years later. It also refers to a pharmaceutical composition comprising said compound, being useful in the treatment of ER alpha positive cancer resistant to therapy in comparison with BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant / ICI). |